OncLive TV

Nageshwara Arvind Dasari, MD, discusses the patient population observed in the phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Nabil Saba, MD, FACP, discusses the disparities seen in clinical trials in head and neck cancer.

Massimo Cristofanilli, MD, discusses the variety of targeted therapies available in metastatic hormone receptor–positive breast cancer.

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

Jonathon B. Cohen, MD, MS, discusses the evolution of treating patients with additional comorbidities in chronic lymphocytic leukemia.

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Suchita Pakkala, MD, discusses the importance for clinical trial enrollment for patients with breast cancer who have brain metastases.

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Cesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.

Melissa L. Johnson, MD, discusses the evolution of frontline treatment in non–small cell lung cancer.

Katherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

Robert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.

Moshe Ornstein, MD, MA, discusses the use of the antibody-drug conjugate enfortumab vedotin in patients with advanced urothelial carcinoma that is refractory to chemotherapy and immunotherapy.

Madan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.

Solly Chedid, MD, discusses the elements of effective therapy in follicular lymphoma.

Krish Patel, MD, discusses the factors to consider when treating patients with relapsed and/or refractory follicular lymphoma.

Nilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.

Sebastian C. Schmid, MD, discusses the use of preoperative radiation therapy plus immunotherapy in urothelial carcinoma.

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Barry Paul, MD, discusses the management of cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome following CAR T-cell therapy in cancer care.

Aaron T. Gerds, MD, MS, discusses the phase 3 VERIFY trial examining rusfertide in patients with polycythemia vera.

Sanjay Popat, MBBS, FRCP, PhD, discusses the investigation of lurbinectedin as a second-line treatment for patients with small cell lung cancer.

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Pedro C. Barata, MD, MSc, discusses the evolving treatment landscape of urothelial cancer.

Srdan Verstovsek, MD, PhD, discusses the potential for rusfertide in polycythemia vera.

Nicolas Girard, MD, PhD, discusses the investigation of lurbinectedin in small cell lung cancer.